FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has Phase 2 data for its endometriosis and immuno-oncology candidates and is in licensing talks.

  • Released interim Phase 2 head and neck cancer results for tosporsertib at ASCO 2026. Source
  • Said it is in talks on global licensing of merigolix. Source

Roles often seen at this stageClinical & PV · BD & licensing · Research & development

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

TiumBio

Develops drug candidates for endometriosis, immuno-oncology and hemophilia, and also runs a drug process development and protein analysis services business (CDAO).

Merigolix (TU2670)

Phase 2

Endometriosis candidate that met statistical significance on its primary endpoint, reduction in menstrual pain, in a Phase 2a trial in five European countries.

Tosporsertib (TU2218)

Phase 2

Immuno-oncology candidate combined with Keytruda; at ASCO 2026 it reported responses in 9 of 12 first-line head and neck cancer patients.

TU7710

Phase 1

Recombinant hemophilia bypassing-agent candidate with extended half-life, in a Phase 1b trial in Europe.

Completion reported

Released interim Phase 2 results of tosporsertib with Keytruda in head and neck cancer in an ASCO 2026 abstract.

Completion reported

Reported record consolidated revenue of 12.3 billion won for 2025.

Official role guide

TiumBio careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 티움바이오 "매출 기반 강화…임상 신약 삼총사, 올해 상업화 원년" ↗머니투데이 · Published 2026-03-20 · Sources checked 2026-11-18 · Original unavailable
  2. 티움바이오, ASCO서 토스포서팁 두경부암 임상 중간 결과 발표 ↗하이뉴스 · Published 2026-05-22 · Sources checked 2026-11-18 · Original unavailable